The cardiovascular safety of antiobesity drugs-analysis of signals in the FDA Adverse Event Report System Database.
Saved in:
| Title: | The cardiovascular safety of antiobesity drugs-analysis of signals in the FDA Adverse Event Report System Database. |
|---|---|
| Authors: | Gorelik E; Division of Clinical Pharmacy, Faculty of Medicine, School of Pharmacy, The Institute for Drug Research, The Hebrew University of Jerusalem, Jerusalem, Israel., Gorelik B, Masarwa R; Division of Clinical Pharmacy, Faculty of Medicine, School of Pharmacy, The Institute for Drug Research, The Hebrew University of Jerusalem, Jerusalem, Israel., Perlman A; Division of Clinical Pharmacy, Faculty of Medicine, School of Pharmacy, The Institute for Drug Research, The Hebrew University of Jerusalem, Jerusalem, Israel., Hirsh-Raccah B; Division of Clinical Pharmacy, Faculty of Medicine, School of Pharmacy, The Institute for Drug Research, The Hebrew University of Jerusalem, Jerusalem, Israel., Matok I; Division of Clinical Pharmacy, Faculty of Medicine, School of Pharmacy, The Institute for Drug Research, The Hebrew University of Jerusalem, Jerusalem, Israel. ilan.matok@ekmd.huji.ac.il. |
| Source: | International journal of obesity (2005) [Int J Obes (Lond)] 2020 May; Vol. 44 (5), pp. 1021-1027. Date of Electronic Publication: 2020 Mar 09. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101256108 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5497 (Electronic) Linking ISSN: 03070565 NLM ISO Abbreviation: Int J Obes (Lond) Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
